Search

Your search keyword '"Katlama, C."' showing total 1,668 results

Search Constraints

Start Over You searched for: Author "Katlama, C." Remove constraint Author: "Katlama, C."
1,668 results on '"Katlama, C."'

Search Results

1. Immunovirological status in people with perinatal and adult-acquired HIV-1 infection: a multi-cohort analysis from France

4. The burden of secrecy in the management of multimorbidity in older people living with HIV aged 70 and over.

5. Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies.

6. EE485 Cost-Effectiveness of a 4 Days-a-Week Triple Therapy in Persons Living with HIV: An Ancillary Study of the Anrs 170 Quatuor Noninferiority Trial

8. HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007–12: impact on susceptibility to first-line strategies

10. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

11. Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study

12. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

17. Differences in HIV cure clinical trial preferences of French people living with HIV and physicians in the ANRS‐APSEC study: a discrete choice experiment

18. Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)

19. No relationship between late HIV diagnosis and social deprivation in newly diagnosed patients in France

20. Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus‐co‐infected patients (ANRS CO13‐HEPAVIH)

21. Prevalence of baseline virological risk factors of increased virological failure to CAB+RPV among ARV-naive patients

23. Uvéites chez les patients vivant avec le VIH : une étude rétrospective multicentrique

24. Comparison of HIV-Infected and Noninfected Patients Undergoing Bariatric Surgery: The ObeVIH Study

25. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0

26. Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial)

27. Post‐HCV cure self‐reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH)

28. No increased risk of Kaposi sarcoma relapse in patients with controlled HIV‐1 infection after switching protease inhibitor‐based antiretroviral therapy

29. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study

31. Levels and determinants of breast and cervical cancer screening uptake in HIV‐infected women compared with the general population in France

32. Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course

33. ATLANTIC: Unverblindete, randomisierte prospektive Studie zum Vergleich konvergenter antiretroviraler Dreifachkombinationen mit einer Protease-lnhibitor-haltigen (divergenten) Standardtherapie nicht vorbehandelter HlV-lnfizierter

35. Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study

36. Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy

40. Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial

41. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

42. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response:a sub-study of the NEAT001/ANRS143 randomized trial

43. No barrier to care, yet disparities in the HIV care continuum in France: a nationwide population study

47. Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission

48. Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity

49. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients

50. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

Catalog

Books, media, physical & digital resources